A Review of Proteases and Antiproteases for Immune Regulation and Potential Therapeutic Application in Pulmonary Fibrosis
Authors:
- Sara Waqas AhmedSASara Waqas Ahmed
- Debananda GogoiDGDebananda Gogoi
- Luke FordeLFLuke Forde
- Mengxin NiuMNMengxin Niu
- Rory BairdRBRory Baird
- Cormac McCarthyCMCormac McCarthy
- Michael P. KeaneMKMichael P. Keane
- Emmet E. McGrathEMEmmet E. McGrath
- Emer Patricia ReevesEREmer Patricia Reeves
Open Access
- 1 January 2025
- journal article
- review article
- Published by S. Karger AG in Journal of Innate Immunity
- Vol. 17 (1) , 468-486
Abstract
Background: Interstitial lung diseases (ILDs) or diffuse parenchymal lung diseases are general terms for a group of over 200 conditions that result from the destruction of cells neighbouring the alveoli, leading to extensive inflammation and fibrosis of the lungs. Although different types of ILD have distinct pathophysiology, clinical display, and advancement, many forms drive irreversible pulmonary fibrosis (PF), leading to progressive functional impairment, respiratory failure, and mortality. Summary: Key components of innate immunity include proteases and their cognate inhibitors, which are involved in respiratory homoeostasis. Alterations to the protease-antiprotease balance can lead to pulmonary disease and fibrotic scarring of the lungs, and over the past two decades, there has been a surge in research exploring their effect on the pathogenesis of ILDs. We have evaluated relevant studies regarding these enzymes in the context of lung fibrosis and have discussed prospects for developing novel treatments. This review will place greater emphasis on the overall effect of proteases and antiproteases to the development of PF, as studied using both in vivo and in vitro models. Key Message: Considering the limited therapeutic interventions, continued research on proteolytic enzymes and their inhibitors is required for the development of novel effective treatments for PF.Keywords
This publication has 160 references indexed in Scilit:
- Granzyme A is an interleukin 1 beta-converting enzyme.Journal of Experimental Medicine, 1995
- Granzymes: exogenous porteinases that induce target cell apoptosisImmunology Today, 1995
- Selective inhibitory effects of the anticoagulant activated protein C on the responses of human mononuclear phagocytes to LPS, IFN- gamma , or phorbol ester.The Journal of Immunology, 1994
- ABNORMALITIES OF PATHWAYS OF FIBRIN TURNOVER IN LUNG LAVAGE OF RATS WITH OLEIC-ACID AND BLEOMYCIN-INDUCED LUNG INJURY SUPPORT ALVEOLAR FIBRIN DEPOSITION1989
- Local abnormalities of coagulation and fibrinolytic pathways that promote alveolar fibrin deposition in the lungs of baboons with diffuse alveolar damage.Journal of Clinical Investigation, 1989
- The collagen substrate specificity of human neutrophil collagenase.Journal of Biological Chemistry, 1987
- Isolation of six cysteine proteinase inhibitors from human urine. Their physicochemical and enzyme kinetic properties and concentrations in biological fluids.Journal of Biological Chemistry, 1986
- ABNORMALITIES IN PATHWAYS OF ALVEOLAR FIBRIN TURNOVER AMONG PATIENTS WITH INTERSTITIAL LUNG-DISEASE1986
- Evidence that a variety of cultured cells secrete protease nexin and produce a distinct cytoplasmic serine protease‐binding factorJournal of Cellular Physiology, 1983
- Protease-nexin: A cellular component that links thrombin and plasminogen activator and mediates their binding to cellsCell, 1980